GlobeNewswire Inc | Jun 16, 2021 08:00AM EDT

June 16, 2021

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the following upcoming investor conferences in June:

-- SVB Leerink CybeRx Series: Liver Disease DayFormat: One-on-one investor meetingsDate: Thursday, June 17, 2021

-- Raymond James Human Health Innovation ConferencePanel Discussion: State of the Union: Current Thinking in NASHDate: Wednesday, June 23, 2021 at 12:00 PM ET

-- Piper Sandler EASL Takeaway DayFormat: One-on-one investor meetingsDate: Monday, June 28, 2021

About 89bio 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The companys lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact: Ryan Martins Chief Financial Officer investors@89bio.com

Media Contact: Peter Duckler 773-343-3069 pduckler@w2ogroup.com